JP2008520242A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008520242A5 JP2008520242A5 JP2007543226A JP2007543226A JP2008520242A5 JP 2008520242 A5 JP2008520242 A5 JP 2008520242A5 JP 2007543226 A JP2007543226 A JP 2007543226A JP 2007543226 A JP2007543226 A JP 2007543226A JP 2008520242 A5 JP2008520242 A5 JP 2008520242A5
- Authority
- JP
- Japan
- Prior art keywords
- age
- macular degeneration
- related macular
- cfh
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010064930 age-related macular degeneration Diseases 0.000 claims 51
- 208000002780 macular degeneration Diseases 0.000 claims 51
- 101150030967 CFH gene Proteins 0.000 claims 39
- 108091033319 polynucleotide Proteins 0.000 claims 39
- 102000040430 polynucleotide Human genes 0.000 claims 39
- 239000002157 polynucleotide Substances 0.000 claims 39
- 239000000523 sample Substances 0.000 claims 39
- 102100035432 Complement factor H Human genes 0.000 claims 32
- 239000013615 primer Substances 0.000 claims 25
- 239000000203 mixture Substances 0.000 claims 22
- 125000003729 nucleotide group Chemical group 0.000 claims 20
- 238000009396 hybridization Methods 0.000 claims 15
- 229920001184 polypeptide Polymers 0.000 claims 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims 15
- 239000002773 nucleotide Substances 0.000 claims 14
- 238000000034 method Methods 0.000 claims 11
- 108020004999 messenger RNA Proteins 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 239000003937 drug carrier Substances 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 238000009007 Diagnostic Kit Methods 0.000 claims 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 5
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 5
- 108020004459 Small interfering RNA Proteins 0.000 claims 3
- 230000000692 anti-sense effect Effects 0.000 claims 3
- 238000001514 detection method Methods 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 108091070501 miRNA Proteins 0.000 claims 3
- 239000002679 microRNA Substances 0.000 claims 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 3
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 2
- 108020003215 DNA Probes Proteins 0.000 claims 2
- 239000003298 DNA probe Substances 0.000 claims 2
- 210000000170 cell membrane Anatomy 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 125000003835 nucleoside group Chemical group 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 108020001019 DNA Primers Proteins 0.000 claims 1
- 239000003155 DNA primer Substances 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 210000001331 nose Anatomy 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000001138 tear Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 210000002105 tongue Anatomy 0.000 claims 1
- 210000000515 tooth Anatomy 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62936304P | 2004-11-18 | 2004-11-18 | |
| US64947905P | 2005-02-02 | 2005-02-02 | |
| US67234605P | 2005-04-18 | 2005-04-18 | |
| PCT/US2005/041664 WO2006062716A2 (en) | 2004-11-18 | 2005-11-18 | Methods and compositions for treating ocular disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012000185A Division JP2012080900A (ja) | 2004-11-18 | 2012-01-04 | 視覚障害を処置するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008520242A JP2008520242A (ja) | 2008-06-19 |
| JP2008520242A5 true JP2008520242A5 (https=) | 2009-01-22 |
Family
ID=36578383
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007543226A Withdrawn JP2008520242A (ja) | 2004-11-18 | 2005-11-18 | 視覚障害を処置するための方法および組成物 |
| JP2012000185A Pending JP2012080900A (ja) | 2004-11-18 | 2012-01-04 | 視覚障害を処置するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012000185A Pending JP2012080900A (ja) | 2004-11-18 | 2012-01-04 | 視覚障害を処置するための方法および組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20090017029A1 (https=) |
| EP (1) | EP1836312B1 (https=) |
| JP (2) | JP2008520242A (https=) |
| KR (1) | KR101290621B1 (https=) |
| CN (2) | CN102618644A (https=) |
| AT (1) | ATE528410T1 (https=) |
| AU (1) | AU2005314461B2 (https=) |
| BR (1) | BRPI0518289A2 (https=) |
| CA (1) | CA2588270A1 (https=) |
| CY (1) | CY1112579T1 (https=) |
| DK (1) | DK1836312T3 (https=) |
| ES (1) | ES2375490T3 (https=) |
| IL (1) | IL183284A (https=) |
| WO (1) | WO2006062716A2 (https=) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004047514A2 (en) | 2002-11-25 | 2004-06-10 | Sequenom, Inc. | Methods for identifying risk of breast cancer and treatments thereof |
| BRPI0506629A (pt) | 2004-02-10 | 2007-05-02 | Univ Colorado | inibição do fator b, a via alternativa do sistema complemento e métodos relacionados |
| US7745389B2 (en) * | 2005-02-14 | 2010-06-29 | University Of Iowa Research Foundation | Methods for treatment of age-related macular degeneration |
| WO2006128006A1 (en) | 2005-05-26 | 2006-11-30 | The Regents Of The University Of Colorado | Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| SG10201804008UA (en) * | 2005-11-04 | 2018-06-28 | Genentech Inc | Use of complement pathway inhibitors to treat ocular diseases |
| WO2007120975A2 (en) * | 2006-02-13 | 2007-10-25 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Variants in complement regulatory genes predict age-related macular degeneration |
| CA2638916A1 (en) * | 2006-02-13 | 2007-08-23 | University Of Iowa Research Foundation | Variants in complement regulatory genes predict age-related macular degeneration |
| US8012683B2 (en) | 2006-02-13 | 2011-09-06 | University Of Iowa Research Foundation | Variants in complement regulatory genes predict age-related macular degeneration |
| US7759304B2 (en) | 2006-06-21 | 2010-07-20 | Regents Of The University Of Colorado | Targeting complement factor H for treatment of diseases |
| EP2479284B1 (en) * | 2006-07-13 | 2017-09-20 | University of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration |
| AU2016204271B2 (en) * | 2006-07-13 | 2018-04-19 | University Of Iowa Research Foundation | Methods and reagents for the treatment and diagnosis of vascular disorders and age-related macular degeneration |
| ES2391788T3 (es) * | 2006-07-26 | 2012-11-29 | Yale University, Inc. | Diagnóstico y tratamiento de degeneración macular relacionada con la edad |
| CN101173314B (zh) * | 2006-10-18 | 2010-12-01 | 四川省医学科学院（四川省人民医院） | 检测老年黄斑变性疾病的试剂盒 |
| TW201716437A (zh) | 2006-11-02 | 2017-05-16 | 建南德克公司 | 人類化之抗-因子ｄ抗體及其用途 |
| GB0701213D0 (en) * | 2007-01-23 | 2007-02-28 | Univ Cardiff | Factor H polymorphisms in the diagnosis and therapy of inflammatory diseases such as age-related macular degeneration |
| WO2008103299A2 (en) | 2007-02-16 | 2008-08-28 | Massachusetts Eye & Ear Infirmary | Methods and compositions for prognosing, detecting, and treating age-related macular degeneration |
| CN101668773B (zh) | 2007-03-14 | 2016-08-31 | 亚力史制药公司 | 人工程化抗b因子抗体 |
| JP5226256B2 (ja) * | 2007-07-26 | 2013-07-03 | ニプロ株式会社 | 加齢黄斑変性症の発症リスクの予測方法 |
| WO2009059321A2 (en) * | 2007-11-01 | 2009-05-07 | University Of Iowa Research Foundation | Rca locus analysis to assess susceptibility to amd and mpgnii |
| US8114592B2 (en) | 2008-03-18 | 2012-02-14 | Cambridge Enterprise Limited | Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof |
| US20110190221A1 (en) * | 2008-03-28 | 2011-08-04 | Apellis Ag | Modulation and repletion/enhancement of the complement system for treatment of trauma |
| CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
| DK2540843T3 (da) * | 2008-11-05 | 2014-09-01 | Genentech Inc | Genetiske polymorfismer ved aldersbetinget makulær degeneration |
| US20120115925A1 (en) * | 2008-12-23 | 2012-05-10 | Massachusetts Eye And Ear Infirmary | Allelic Variants Associated with Advanced Age-Related Macular Degeneration |
| KR100937720B1 (ko) * | 2009-04-20 | 2010-01-20 | 전남대학교산학협력단 | ＣＦＨ 또는 ＡｐｏＨ를 급성골수성백혈병 관해 진단용 생화학적 마커로 사용하는 방법 |
| WO2011003098A1 (en) | 2009-07-02 | 2011-01-06 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
| CA2795311A1 (en) | 2009-11-05 | 2011-05-12 | Taligen Therapeutics, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
| US20130011857A1 (en) | 2010-02-12 | 2013-01-10 | Cemm Forschungszentrum Fur Molekulare Medizin Gmbh | Complement factor h for oxidative stress disease conditions |
| BR112012029067A2 (pt) | 2010-05-14 | 2019-09-24 | Univ Colorado Regents | grupos-alvo de receptor do complemento 2 (cr2) melhorados. |
| WO2011153234A2 (en) * | 2010-06-01 | 2011-12-08 | University Of Kentucky Research Foundation | Methods of inhibiting alu rna and therapeutic uses thereof |
| WO2011163394A2 (en) | 2010-06-22 | 2011-12-29 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of neuropathic pain |
| SG186397A1 (en) | 2010-06-22 | 2013-01-30 | Univ Colorado Regents | Antibodies to the c3d fragment of complement component 3 |
| JP2014502953A (ja) | 2010-08-16 | 2014-02-06 | ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | 細胞透過性治療薬の鼻腔内送達 |
| FR2983212A1 (fr) | 2011-11-28 | 2013-05-31 | Lfb Biotechnologies | Aptameres anti-fh, procede pour leur obtention et utilisations |
| FR2988298A1 (fr) * | 2012-03-23 | 2013-09-27 | Lfb Biotechnologies | Facteur h pour son utilisation comme molecule antioxydante |
| US9803005B2 (en) | 2012-05-24 | 2017-10-31 | Alexion Pharmaceuticals, Inc. | Humaneered anti-factor B antibody |
| CN102707068B (zh) * | 2012-05-31 | 2015-03-18 | 北京大学 | 补体h因子用作甲基苯丙胺成瘾患者的基因表达产物中的应用 |
| JP2015535212A (ja) | 2012-08-17 | 2015-12-10 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト | 補体活性化を検出するための組成物および方法 |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| MX366404B (es) | 2012-11-15 | 2019-07-08 | Apellis Pharmaceuticals Inc | Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y composiciones y metodos relacionados. |
| AU2014236778B2 (en) | 2013-03-14 | 2019-01-03 | Baxalta GmbH | Factor H for transplantation |
| JP5721150B2 (ja) * | 2013-03-14 | 2015-05-20 | 学校法人 埼玉医科大学 | 加齢黄斑変性症の発症リスクの予測方法 |
| WO2014151923A1 (en) | 2013-03-14 | 2014-09-25 | Baxter International Inc. | Factor h for treatment of rheumatoid arthritis |
| AU2013202965B2 (en) | 2013-03-15 | 2016-07-21 | Takeda Pharmaceutical Company Limited | Improved method for producing factor h from a plasma precipitation fraction |
| WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| SG11201601044XA (en) | 2013-08-12 | 2016-03-30 | Genentech Inc | Compositions and method for treating complement-associated conditions |
| US20150093331A1 (en) * | 2013-10-01 | 2015-04-02 | OncoLock Co., Ltd. | Biomarkers for breast cancer |
| KR102131973B1 (ko) * | 2013-12-30 | 2020-07-08 | 주식회사 케이티 | 개인 건강관리 방법 및 시스템 |
| ES2824262T3 (es) * | 2014-02-26 | 2021-05-11 | Allergan Inc | Anticuerpos contra componente C5 del complemento |
| US10155983B2 (en) | 2014-03-31 | 2018-12-18 | Machaon Diagnostics, Inc. | Method of diagnosis of complement-mediated thrombotic microangiopathies |
| AU2015253042A1 (en) | 2014-05-01 | 2016-10-20 | Genentech, Inc. | Anti-factor D antibody variants and uses thereof |
| KR102314785B1 (ko) * | 2015-04-21 | 2021-10-19 | 인제대학교 산학협력단 | 신규한 황반변성 진단용 마커 및 황반변성 진단방법 |
| US11903994B2 (en) | 2015-10-07 | 2024-02-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens |
| US10407510B2 (en) | 2015-10-30 | 2019-09-10 | Genentech, Inc. | Anti-factor D antibodies and conjugates |
| EP3368090A1 (en) | 2015-10-30 | 2018-09-05 | H. Hoffnabb-La Roche Ag | Anti-factor d antibody variant conjugates and uses thereof |
| CN106248968A (zh) * | 2015-11-01 | 2016-12-21 | 李倩 | 一种用于检测眼科疾病的试剂盒及其检测方法 |
| WO2017096031A1 (en) * | 2015-12-03 | 2017-06-08 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf |
| KR102011182B1 (ko) * | 2016-10-07 | 2019-08-16 | 단국대학교 천안캠퍼스 산학협력단 | 익상편 과발현 유전자 및 이의 용도 |
| IL269844B2 (en) | 2017-04-07 | 2025-01-01 | Apellis Pharmaceuticals Inc | Dosage regimens and related compositions and methods |
| WO2019118938A1 (en) | 2017-12-15 | 2019-06-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
| US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
| US20210338838A1 (en) * | 2018-07-20 | 2021-11-04 | University Of Utah Research Foundation | Gene therapy for macular degeneration |
| KR102302571B1 (ko) * | 2019-03-07 | 2021-09-16 | (주)레티마크 | 나이관련 황반변성 진단용 복합 마커 및 이의 용도 |
| CA3167756A1 (en) * | 2020-02-04 | 2021-08-12 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with son of sevenless 2 (sos2) inhibitors |
| KR102333953B1 (ko) * | 2020-07-10 | 2021-12-02 | 인제대학교 산학협력단 | 신규한 황반변성 진단용 유전자 마커 |
| CN113293206A (zh) * | 2021-07-23 | 2021-08-24 | 西安医臻生物医药科技有限公司 | 一种快速鉴别老年黄斑病变风险的方法及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1284931C (en) * | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| CA2336703A1 (en) * | 1998-07-10 | 2000-01-20 | The University Of Sydney | Prophylactic treatments of neovascularisation in macular degeneration |
| AU2001245489A1 (en) * | 2000-03-07 | 2001-09-17 | Whitehead Institute For Biomedical Research | Human single nucleotide polymorphisms |
| JP4764590B2 (ja) * | 2000-04-29 | 2011-09-07 | ユニバーシティー オブ アイオワ リサーチ ファウンデーション | 黄班変性関連疾患の診断および治療 |
| CN1466953A (zh) * | 2003-01-15 | 2004-01-14 | 哈佛东方生物医药（云南）有限公司 | 预防治疗老年黄斑变性的复合制剂 |
| US7745389B2 (en) * | 2005-02-14 | 2010-06-29 | University Of Iowa Research Foundation | Methods for treatment of age-related macular degeneration |
-
2005
- 2005-11-18 JP JP2007543226A patent/JP2008520242A/ja not_active Withdrawn
- 2005-11-18 WO PCT/US2005/041664 patent/WO2006062716A2/en not_active Ceased
- 2005-11-18 CN CN2012100868621A patent/CN102618644A/zh active Pending
- 2005-11-18 AU AU2005314461A patent/AU2005314461B2/en not_active Ceased
- 2005-11-18 AT AT05851755T patent/ATE528410T1/de active
- 2005-11-18 ES ES05851755T patent/ES2375490T3/es not_active Expired - Lifetime
- 2005-11-18 KR KR1020077013736A patent/KR101290621B1/ko not_active Expired - Fee Related
- 2005-11-18 CA CA002588270A patent/CA2588270A1/en not_active Abandoned
- 2005-11-18 US US11/791,025 patent/US20090017029A1/en not_active Abandoned
- 2005-11-18 CN CN2005800467319A patent/CN101142321B/zh not_active Expired - Fee Related
- 2005-11-18 DK DK05851755.8T patent/DK1836312T3/da active
- 2005-11-18 EP EP05851755A patent/EP1836312B1/en not_active Expired - Lifetime
- 2005-11-18 BR BRPI0518289-1A patent/BRPI0518289A2/pt not_active IP Right Cessation
-
2007
- 2007-05-17 IL IL183284A patent/IL183284A/en not_active IP Right Cessation
-
2011
- 2011-09-16 US US13/235,289 patent/US20120135000A1/en not_active Abandoned
-
2012
- 2012-01-04 JP JP2012000185A patent/JP2012080900A/ja active Pending
- 2012-01-11 CY CY20121100030T patent/CY1112579T1/el unknown
-
2013
- 2013-09-26 US US14/038,602 patent/US20140018306A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008520242A5 (https=) | ||
| CN110791560B (zh) | 一种用于阿尔茨海默病诊断和/或治疗的miRNA标志物 | |
| JP2009502115A5 (https=) | ||
| JP2006500949A5 (https=) | ||
| JP2022523301A5 (https=) | ||
| WO2007139811A1 (en) | Methods and kits for linking polymorphic sequences to expanded repeat mutations | |
| SG190570A1 (en) | Antiviral therapy | |
| CN106047991A (zh) | 用于检测川崎病的方法及试剂盒 | |
| EP2191274A1 (en) | Method for predicting the response of a subject suffering from a viral infection of the liver to an antiviral therapy | |
| JP2003508022A5 (https=) | ||
| CA3116522A1 (en) | A method of detecting small rna | |
| CN106434982A (zh) | 缺血性脑卒中相关的分子标记物及其应用 | |
| CN105063194A (zh) | 一种帕金森的诊断标志物及其应用 | |
| CN111733227A (zh) | 特发性视神经炎诊断分子标记物circRNA、试剂盒及应用 | |
| CN106661618B (zh) | Dna甲基化状态作为酒精使用和戒酒的生物标志物 | |
| CN111411152A (zh) | 人源环状rna在制备心脏疾病相关产品中的应用 | |
| JP2009523004A5 (https=) | ||
| JP2010501162A5 (https=) | ||
| CN109609649B (zh) | 一种用于直肠腺癌诊疗的lncRNA | |
| CN102851359A (zh) | 检测SLC26A4基因c.665G＞T突变的试剂盒 | |
| EP3845666B1 (en) | A method of detecting small rna | |
| JP2005034151A5 (https=) | ||
| AU2021107694A4 (en) | A method of detecting small rna | |
| JP2022515838A5 (https=) | ||
| CN108752452B (zh) | Sars及其突变体的应用 |